Acute ishcemic stroke
Conditions
Interventions
Treatment Group:Atorvastatin 20mg/day or rosuvastatin 10mg/day for 6 weeks, Plus 140 mg of evolocumab by subcutaneous injection every 2 weeks
continuous administration for 6 weeks, of which a total of 6 doses of evolocumab
Control Group:Atorvastatin 20mg/day or rosuvastatin 10mg/day for 6 weeks, Plus 140 mg of evolocumab placeo by subcutaneous injection every 2 weeks
continuous administration for 6 weeks, of which a total of 6 doses of evolocumab placeo
Sponsors
The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China.
Longgang district People’s Hospital of Shenzhen
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Over 18 years of age, regardless of gender; 2. Meet the diagnostic criteria of acute ischemic stroke 3. The time of admission was within 24 hours after onset. 4. Good compliance, agreed to sign the informed consent, follow-up.
Exclusion criteria
Exclusion criteria: 1.Intolerant to both atorvastatin and rosuvastatin; 2. History of major surgery or endovascular treatment within 3 months prior to the screening period; 3. Arterial stenosis or occlusion not caused by atherosclerosis, such as arterial dissection, moya-moya disease, vasculitis, radiation vascular disease, or fibromuscular dysplasia; 4. Abnormal liver function (ALT > 3 times the upper limit of normal); 5. Renal dysfunction (glomerular filtration rate (eGFR) <45 mL/min/1.73m2 at screening); 6. Thrombocytopenia (PLT<100G/L); 7. The expected survival time is not more than 6 months; 8. Other known serious life-threatening disease (such as hematologic disease, malignancy), unstable vital signs or need for continuous monitoring, or moribund state during screening; 9. Patients have been included in other studies that conflict with this study; 10. Known sensitivity to any of the products or components to be administered during dosing; 11. Pregnant, breastfeeding or planning pregnancy, and other conditions that the investigator considers the patient unsuitable for enrollment; 12. Other conditions that the investigator considered inappropriate for enrollment
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| mRS score at 90 days;NIH stroke score at 90 days; | — |
Secondary
| Measure | Time frame |
|---|---|
| Changes in NIHSS compared with pre-treatment; Cerebral Bleeding Rate;Death or severe disability rate; | — |
Countries
China
Contacts
Public ContactChuancheng REN
The Second Affiliated Hospital, School of Medicine, The Chinese University of Hong Kong, Shenzhen, Guangdong, 518172, P.R. China Longgang district People’s Hospital of Shenzhen
Outcome results
None listed